Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in TNFi-experienced radiographic axial spondyloarthritis
NCT02696798Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2016
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in ankylosing spondylitis (AS) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Assessment of Spondyloarthritis International Society 40 Response at 16 weeks. Started Apr 2016; status: completed.
02
Drugs
ixekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02696798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696798.